Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
Trial Parameters
Brief Summary
The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women. The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy. Researchers will compare Li-SWT with oral solifenacin succinate, a commonly used antimuscarinic medication for OAB. Participants will be randomly assigned to receive either Li-SWT once weekly for 8 weeks or solifenacin 5 mg taken orally once daily for 12 months. All participants will complete symptom questionnaires and three-day voiding diaries and will undergo uroflowmetry, post-void residual measurement, and filling cystometry at specified time points during follow-up.
Eligibility Criteria
Inclusion Criteria: * OAB symptoms persisting for ≥3 months. * OAB Symptom Score (OABSS) ≥7. * Ability and willingness to provide informed consent Exclusion Criteria: * Active urinary tract infection. * Stress urinary incontinence as primary diagnosis. * Pelvic organ prolapse stage ≥II. * History of pelvic radiation or surgery within 6 months. * Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout. * Pregnancy or breast feeding. * Neuropathic diseases or psychological disorders. * History of urogenital malignancy. * Uncontrolled DM (HbA1c \> 6.8) * Uncorrected coagulopathy or severe cardiovascular disease. * Contraindication to solifenacin e.g.: closed angle glaucoma)